Kestra Medical Technologies (NASDAQ:KMTS) Trading 7.5% Higher – What’s Next?

Posted by Geri Gentry on Jul 1st, 2026

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) shares were up 7.5% during mid-day trading on Wednesday . The stock traded as high as $26.47 and last traded at $27.36. Approximately 17,413 shares traded hands during trading, a decline of 95% from the average session volume of 327,786 shares. The stock had previously closed at $25.44.

Analyst Ratings Changes

Several research firms recently weighed in on KMTS. Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. BTIG Research reaffirmed a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, The Goldman Sachs Group decreased their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Hold” and a consensus price target of $27.40.

View Our Latest Research Report on Kestra Medical Technologies

Kestra Medical Technologies Stock Performance

The company has a 50 day moving average of $21.20 and a two-hundred day moving average of $22.78. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The company has a market capitalization of $1.60 billion, a PE ratio of -6.95 and a beta of 0.83.

Insider Buying and Selling at Kestra Medical Technologies

In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $20.81, for a total value of $312,150.00. Following the completion of the transaction, the insider directly owned 395,467 shares in the company, valued at $8,229,668.27. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 45,000 shares of company stock valued at $927,150. 3.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of institutional investors and hedge funds have recently made changes to their positions in KMTS. Farther Finance Advisors LLC bought a new stake in shares of Kestra Medical Technologies in the 4th quarter worth approximately $31,000. Russell Investments Group Ltd. increased its position in Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in Kestra Medical Technologies in the fourth quarter worth $72,000. Finally, Brown Brothers Harriman & Co. grew its stake in shares of Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares during the last quarter.

About Kestra Medical Technologies

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.